FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. **BSA 01-29**	SERIAL NO. Unassigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Dewey, et al.	
(Use several sheets if necessary)	FILING DATE Herewith	GROUP Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
TK		3,639,607	February 1, 1972	Phillips, Jack	7		
		4,540,582	September 10, 1985	Seiler, et al.			
		4,595,697	June 17, 1986	Seiler, et al.			
		4,621,145	November 4, 1986	Frieben, et al.			
		5,189,064	February 23, 1993	Blum, et al.			
		5,869,498	February 9, 1999	Mayer, et al.			
		5,942,241	August 24, 1999	Chasin, et al.			
		5,948,787	September 7, 1999	Merrill, et al.			
		5,958,459	September 28, 1999	Chasin, et al.			
		5,968,551	October 19, 1999	Oshlack, et al.			
		6,007,841	December 28, 1999	Caruso, Frank			
		6,054,451	April 25, 2000	Caruso, Frank			
		6,077,538	June 20, 2000	Merrill, et al.			
		6,107,330	August 22, 2000	Nabeshima, et al.			
		6,103,261	August 15, 2000	Chasin, et al.			
		6,143,322	November 7, 2000	Sackler, et al.			

EXAMINER TK DATE CONSIDERED 6/18/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. **BSA 01-29**	SERIAL NO. Unassigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Dewey, et al.	
(Use several sheets if necessary)	FILING DATE Herewith	GROUP Unassigned

		6,143,353	November 7, 2000	Oshlack, et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES	TRANSLATION NO
JC		WO 89/03211	April 20, 1989	PCT				
		WO 98/00130	January 8, 1998	PCT				
		WO 99/21540	May 6, 1999	PCT				
		WO 00/07583	February 17, 2000	PCT				
		WO 00/23059	April 27, 2000	PCT				
		WO 00/44374	August 3, 2000	PCT				
		WO 00/50020	August 31, 2000	PCT				
		WO 00/61140	October 19, 2000	PCT				
		WO 00/66108	November 9, 2000	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1. JC Morgan et al., "Longterm Cocaine Administration May Alter Specific Gabaergic Pathways", Abstracts Society for Neuroscience, 23:1942 (1997).
2. JC Kushner et al., "Comparison of the Effects of Vigabatrin on Cocaine Self-Administration and Food Reinforcement", Abstracts Society for Neuroscience, 23:1942 (1997).

EXAMINER JC DATE CONSIDERED 6/18/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. **BSA 01-29**	SERIAL NO. Unassigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Dewey, et al.	
(Use several sheets if necessary)	FILING DATE Herewith	GROUP Unassigned

3. Dewey et al., "GABAergic Attenuation of Cocaine-Induced Dopamine Release and Locomotor Activity", Synapse, 25:393-398 (1997).

4. Morgan et al., "Effects of Pharmacologic Increases in Brain GABA Levels on Cocaine-Induced Changes in Extracellular Dopamine", Synapse 28:60-65 (1998).

5. Kushner et al., "Gamma-vinyl GABA Attenuates Cocaine-Induced Lowering of Brain Stimulation Reward Thresholds", Psychopharmacology 133:383-388 (1997).

6. Porter et al., "Antiepileptic Drugs", Basic and Clinical Pharmacology, ed. by Katzung, B.G., Appelton and Lange, Stamford, CT pp. 386-408 (1998).

7. Takada et al., "Drug Dependence Study on Vigabatrin in Rhesus Monkeys and Rats", Arzneim.-Forsch Drug Res 47(II), 1087-1092 (1997).

8. Nisell et al., "Nicotine Dependence, Midbrain Dopamine Systems and Psychiatric Disorders", Pharmacology & Toxicology 76:157-162 (1995).

9. Nisell et al., "Infusion of Nicotine in the Ventral Tegmental Area or the Nucleus Accumbens of the Rat Differentially Affects Accumbal Dopamine Release", Pharmacology & Toxicology, 75:348-352 (1994).

10. Fudala et al., "Pharmacologic Characterization of Nicotine-Induced Conditioned Place Preference", Pharmacol Biochem Behav 22(2) 237-241 (1985)

11. Clarke et al., "Apparent Absence of Nicotine-Induced Conditioned Place Preference in Rats" Psychopharmacology, 92: 84-88 (1987).

12. Clarke et al., " Evidence That Mesolimbic Dopaminergic Activation Underlies the Locomotor Stimulant Action of Nicotine in Rats", The Journal of Pharmacology and Experimental Therapeutics, 246:701-708 (1988).

13. Henningfield et al., "Control of Behavior by Intravenous Nicotine Injections in Human Subjects", Pharmacology Biochemistry & Behavior, 19:1021-1026 (1983).

EXAMINER [signature] DATE CONSIDERED 6/18/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. **BSA 01-29**	SERIAL NO. Unassigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Dewey, et al.	
(Use several sheets if necessary)	FILING DATE Herewith	GROUP Unassigned

14. Jarvik et al., "Pharmacological Treatment of Tobacco Dependence", Pharmacology Biochemistry & Behavior, 30:279-294 (1988).

15. Henningfield et al., "Cigarette Smokers Self-Administer Intravenous Nicotine", Pharmacology Biochemistry & Behavior 19:887-890 (1983).

16. Nisell et al., "Systemic Nicotine-Induced Dopamine Release in the Rat Nucleus Accumbens is Regulated by Nicotinic Receptors in the Ventral Tegmental Area", Synapse 16:36-44 (1994).

17. Pontieri et al., "Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs" Nature 382:255-257 (1996).

18. Di Chiara et al., "Drugs Abused by Humans Preferentially Increase Synaptic Dopamine Concentrations in the Mesolimbic System of Freely Moving Rats", Proc. Natl. Acad. Sci. USA, 85:5274-5278 (1988).

19. Damsma et al., "Lack of Tolerance to Nicotine-Induced Dopamine Release in the Nucleus Accumbens", European Journal of Pharmacology, 168:363-368 (1989).

20. Imperato et al., "Nicotine Preferentially Stimulates Dopamine Release in the Limbic System of Freely Moving Rats" European Journal of Pharmacology, 132:337-338 (1986).

21. Brazell et al., "Acute Administration of Nicotine Increases the *In Vivo* Extracellular Levels of Dopamine, 3,4-Dihydroxyphenylacetic Acid and Ascorbic Acid Preferentially in the Nucleus Accumbens of the Rat: Comparison with Caudate-Putamen", Neuropharmacology 29:1177-1185 (1990).

22. Horan et al., "Nicotine Produces Conditioned Place Preference in Lewis But Not Fischer 344 Rats", Synapse 26:93-94 (1997).

23. Lepore et al., "Conditioned Place Preference Induced By Δ^9-Tetrahydrocannabinol: Comparison with Cocaine, Morphine, and Food Reward", Life Sciences, 56:2073-2080 (1995).

24. Sora et al., "Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice" Proc. Natl. Acad. Sci. USA 95:7699-7704 (1998).

EXAMINER [signature] DATE CONSIDERED 6/18/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. **BSA 01-29**	SERIAL NO. Unassigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Dewey, et al.	
(Use several sheets if necessary)	FILING DATE Herewith	GROUP Unassigned

25. Valentine et al., "Self-Administration in Rats Allowed Unlimited Access to Nicotine" Psychopharmacology, 133:300-305 (1997).

26. Eliot L. Gardner, "6 Brain Reward Mechanisms", Substance Abuse: A Comprehensive Textbook, p.51-85 (1997).

27. Marshall et al., " Presynaptic Nicotinic Modulation of Dopamine Release in the Three Ascending Pathways Studied by In Vivo Microdialysis: Comparison of Naive and Chronic Nicotine-Treated Rats" Journal of Neurochemistry, 68:1511-1519 (1997).

28. M.-F. Chesselet, "Presynaptic Regulation of Neurotransmitter Release in the Brain", Neuroscience 12:347-375 (1984).

29. Lacey et al., "On the Potassium Conductance Increase Activated by $GABA_B$ and Dopamine D_2 Receptors in Rat Substantia Nigra Neurones" Journal of Physiology 401:437-453 (1988).

30. Grant et al., "Vigabatrin: A Review of its Pharmacodynamic an Pharmacokinetic Properties, and Therapeutic Potential in Epilepsy and Disorders of Motor Control" Drugs 41 6:889-926 (1991).

31. Jung et al., "Vinyl GABA (4-amino-hex-5-enoic acid). A New Selective Irreversible Inhibitor of GABA-T: Effects on Brain GABA Metabolism in Mice" Neurochem. 29:797-802 (1977).

32. Tsuji et al., "~~Activation of Ventral Tegmental $GABA_B$~~ Receptors Inhibits Morphine-Induced Place Preference in Rats" European Journal of Pharmacology 313:169-173 DATE NEEDED

33. Roberts et al., "Baclofen Suppression of Cocaine Self-Administration: Demonstration Using a Discrete Trials Procedure" Psychopharmacology 131:271-277 (1997).

34. Bolser et al., "The Pharmacology of SCH 50911: A Novel, Orally-Active GABA-B Receptor Antagonist" The Journal of Pharmacology and Experimental Therapeutics 274:1393-1398 (1995).

35. Roberts et al., "Baclofen Attenuates the Reinforcing Effects of Cocaine in Rats" Neuropsychopharmacology 15:417-423 (1996).

EXAMINER [signature] DATE CONSIDERED 6/18/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. **BSA 01-29**	SERIAL NO. Unassigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Dewey, et al.	
(Use several sheets if necessary)	FILING DATE Herewith	GROUP Unassigned

36. Derek van der Kooy, "Place Conditioning: A Simple and Effective Method for Assessing the Motivational Properties of Drugs" M.A. Bozarth, Ed., Springer-Verlag, New York, pp. 229-241 (1987).

37. Hurt et al., "A Comparison of Sustained-Release Bupropion and Placebo for Smoking Cessation" The New England Journal of Medicine 337:1195:1202 (1997).

38. Volkow et al., "Imaging Endogenous Dopamine Competition With [^{11}C] Raclopride in the Human Brain" Synapse 16:255-262 (1994).

39. Logan et al., "Graphical Analysis of Reversible Radioligand Binding from Time-Activity Measurements Applied to [N-^{11}C-methyl]-(-)-Cocaine PET Studies in Human Subjects" Journal of Cerebral Blood Flow and Metabolism 10:740-747 (1990).

40. Dewey et al., "A Novel Strategy for the Treatment of Cocaine Addiction" Synapse 30:119-129 (1998).

41. Dewey et al., "Striatal Binding of the PET Ligand ^{11}C-Raclopride is Altered by Drugs that Modify Synaptic Dopamine Levels" Synapse 13:350-356 (1993).

42. Dewey et al. "GABAergic Inhibition of endogenous Dopamine Release Measured *in vivo* with ^{11}C-Raclopride and Positron Emission Tomography" The Journal of Neuroscience 12(10):3773-3780 (1992).

43. Dewey et al., "Effects of Central Cholinergic Blockade on Striatal Dopamine Release Measured with Positron Emission Tomography in Normal Human Subjects" Proc. Natl. Acad. Sci. USA 90:11816-11820 (1993).

44. Buckland et al., "Amphetamine and Vigabatrin Down Regulate Aromatic L-amino acid Decarboxylase mRNA levels" Molecular Brain Research 35:69-76 (1996).

45. Cubells et al., "*In Vivo* Action of Enzyme-Activated Irreversible Inhibitors of Glutamic Acid Decarboxylase and γ-Aminobutyric Acid Transaminase in Retina vs. Brain" The Journal of Pharmacology and Experimental Therapeutics 238:508-514 (1986).

46. Herbert D. Kleber, "Treatment of Cocaine Abuse: Pharmacotherapy" Cocaine Scientific and Social Dimensions p.195-206 (1992).

EXAMINER [signature] DATE CONSIDERED 6/18/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. **BSA 01-29**	SERIAL NO. Unassigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Dewey, et al.	
(Use several sheets if necessary)	FILING DATE Herewith	GROUP Unassigned

47. ~~Ritz et~~ al., "Psychostimulant Drugs and a Dopamine Hypothesis Regarding Addiction: Update on recent ~~research~~" Biochem. Soc. Symp. 59:51-64. No Date

48. Sherif et al., "Basic Aspects of GABA-transmission in Alcoholism, with Particular Reference to GABA-transaminase" European Neuropsychopharmacology 7:1-7(1997).

49. Dewey et al., "A New GABAergic strategy for treating cocaine addiction" J. Nuclear Med. 39:99-100 (1998).

50. Morgan et al., "Vigabatrin Attenuates Cocaine-Induced Changes in Brian Dopamine Concentrations" J. Nuclear Med. 38:11p (1997).

51. Kushner et al., The irreversible Gamma-aminobutyric acid (GABA) transaminase inhibitor Gamma-vinyl-GABA blocks cocaine self-administration in rats" J. Pharmacology and Experimental Therapeutics 290:797-802 (1999).

52. Dewey et al., "A Pharmacologic Strategy for the Treatment of Nicotine Addiction" Synapse 31:76-86 (1999).

53. Meier, et al., "Medicine Merchants/Uses and Abuses, Use of Painkiller Grows Quickly, Along with Widespread Abuse", New York Times, A1 (2001).

EXAMINER [signature] DATE CONSIDERED 6/18/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.